1
|
Slušná ĽK, Balog M. Review of Indicators in the Context of Biobanking. Biopreserv Biobank 2023; 21:318-326. [PMID: 36099204 DOI: 10.1089/bio.2022.0073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background: Biobanks that intend to serve as high-performing and stable elements of an innovative research ecosystem must have an established system for regular measurement and evaluation using appropriately set indicators. The main objective of this study was to provide a comprehensive overview of indicators in the context of biobanking, with new perspectives to highlight the existence of numerous options and introduce indicators that could help overcome problems associated with the difficult assessment of the impact of biobanks. Methods: A literature review was performed to identify publications relevant to the topic of indicators in biobanking. The Web of Science Core Collection and PubMed databases were searched using specific keywords. In addition, three articles that focused on indicators designed for the evaluation of research infrastructures were included in the review. Results: Based on the scientific literature for the biobanking field, many types of quantitative and qualitative indicators exist. They are mainly related to the quantity and quality of data and samples, their distribution, the monitoring of research projects, and subsequent publication outputs. The indicators identified in the biobanking literature primarily focus on the outcome, not the impact. Conclusions: Indicators identified in the biobanking literature may be further expanded with suggestions designed for other types of research infrastructures, while considering the context where biobanks operate and the needs of individual biobanking stakeholders. The establishment of a comprehensive monitoring system that captures all necessary elements is crucial for modern biobanks.
Collapse
Affiliation(s)
| | - Miroslav Balog
- Centre of Social and Psychological Sciences, SAS, Bratislava, Slovakia
| |
Collapse
|
2
|
Borisova AL, Pokrovskaya MS, Meshkov AN, Kontsevaya AV, Drapkina OM. Risk management in biobanking. КАРДИОВАСКУЛЯРНАЯ ТЕРАПИЯ И ПРОФИЛАКТИКА 2022. [DOI: 10.15829/1728-8800-2022-3400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Risk management is a key aspect of the organization and management of biobanks, which is part of the overall quality management system aimed at early detection, analysis and minimization of events, that can lead to negative consequences for the biobank, as well as affect the quality of biosamples and related data. The article presents the biobanking risk classification with the description of each category.Aim. To develop and implement the methodology for identification, analysis, evaluation and development of risk management measures for the biobanking process in the biobank of the National Medical Research Center for Therapy and Preventive Medicine.Material and methods. We present the methodology of the risk management process developed on the basis of the literary data, world experience and experience of the biobank of the National Medical Research Center for Therapy and Preventive Medicine.Results. The biobanking risk management procedure was developed and implemented in the biobank of the National Medical Research Center for Therapy and Preventive Medicine in 2020. The work carried out made it possible to identify, analyze and evaluate a wide range of potential negative events and actions that could lead to biobank damage, both in the form of financial losses and ethical and technical issues related to the biobanking process. A significant reduction in the frequency of emergency events and the high stability of the biobank operation under the influence of various external factors prove the effectiveness of the approach used.Conclusion. The creation and maintenance of a risk management system in the biobank allows, in combination with other measures, to ensure the safety and high quality of the procedures for collecting, processing and long-term storage of biomaterial and related data by creating an environment that rules out or minimizes the impact of various risks.
Collapse
Affiliation(s)
- A. L. Borisova
- National Medical Research Center for Therapy and Preventive Medicine
| | - M. S. Pokrovskaya
- National Medical Research Center for Therapy and Preventive Medicine
| | - A. N. Meshkov
- National Medical Research Center for Therapy and Preventive Medicine
| | - A. V. Kontsevaya
- National Medical Research Center for Therapy and Preventive Medicine
| | - O. M. Drapkina
- National Medical Research Center for Therapy and Preventive Medicine
| |
Collapse
|
3
|
Boutin NT, Schecter SB, Perez EF, Tchamitchian NS, Cerretani XR, Gainer VS, Lebo MS, Mahanta LM, Karlson EW, Smoller JW. The Evolution of a Large Biobank at Mass General Brigham. J Pers Med 2022; 12:1323. [PMID: 36013271 PMCID: PMC9410531 DOI: 10.3390/jpm12081323] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2022] [Revised: 08/03/2022] [Accepted: 08/10/2022] [Indexed: 12/14/2022] Open
Abstract
The Mass General Brigham Biobank (formerly Partners HealthCare Biobank) is a large repository of biospecimens and data linked to extensive electronic health record data and survey data. Its objective is to support and enable translational research focused on genomic, environmental, biomarker and family history associations with disease phenotypes. The Biobank has enrolled more than 135,000 participants, generated genomic data on more than 65,000 of its participants, distributed approximately 153,000 biospecimens, and served close to 450 institutional studies with biospecimens or data. Although the Biobank has been successful, based on some measures of output, this has required substantial institutional investment. In addition, several challenges are ongoing, including: (1) developing a sustainable cost model that doesn't rely as heavily on institutional funding; (2) integrating Biobank operations into clinical workflows; and (3) building a research resource that is diverse and promotes equity in research. Here, we describe the evolution of the Biobank and highlight key lessons learned that may inform other efforts to build biobanking efforts in health system contexts.
Collapse
Affiliation(s)
| | | | | | | | | | - Vivian S. Gainer
- Mass General Brigham Research Information Science & Computing, Boston, MA 02115, USA
| | - Matthew S. Lebo
- Mass General Brigham Personalized Medicine, Boston, MA 02115, USA
- Brigham and Women’s Hospital, Boston, MA 02115, USA
| | - Lisa M. Mahanta
- Mass General Brigham Personalized Medicine, Boston, MA 02115, USA
| | - Elizabeth W. Karlson
- Mass General Brigham Personalized Medicine, Boston, MA 02115, USA
- Brigham and Women’s Hospital, Boston, MA 02115, USA
| | - Jordan W. Smoller
- Mass General Brigham Personalized Medicine, Boston, MA 02115, USA
- Massachusetts General Hospital, Boston, MA 02114, USA
| |
Collapse
|
4
|
Economics of Biobanking: Business or Public Good? Literature Review, Structural and Thematic Analysis. SOCIAL SCIENCES-BASEL 2022. [DOI: 10.3390/socsci11070288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
This paper reviewed the relevant scientific literature on the business and economics of biobanking to explore key themes and paradigms. The structural properties of the literature were investigated, such as key authors, journals, studies, as well as co-citation and co-authorship networks; the study revealed that the research on business and economics is a niche area within the vast biobanking literature. The research is concentrated in a relatively small number of journals, institutions, and countries, which is rather surprising given the substantial public investment in and concerns about biobank sustainability. The structural analysis also suggested major themes in research on biobanking business and economics and noted shifts in focus on specific themes. The commercialisation of samples is more acknowledged than before but under the condition of equitable sharing of benefits across various stakeholders. Most biobanks are heavily subsidised by the public sector and are considered public goods rather than business enterprises. This is OK, but underutilisation of specimens and low rates of cost recovery suggest that the current mainstream operating model is hardly sustainable. With many biobanks maturing, long-term sustainability became a key topic of the discussion on biobanking trends.
Collapse
|
5
|
Alves A, Gibbon A, Carvalho S, Rodriguez-Justo M, Miranda E. Biobank and Pathology Facility: A Successful Combination. J Biomol Tech 2022; 33:3fc1f5fe.a423c94f. [PMID: 35837002 PMCID: PMC9258917 DOI: 10.7171/3fc1f5fe.a423c94f] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
Financial sustainability in biobanks has recently become a key issue globally, as biorepositories struggle to balance limited external funding and high operating costs. To maximize governance and operational efficiency, the Pathology Facility and the University College London (UCL)/UCL Hospitals Biobank for Studying Health and Disease ("the Biobank") have been grouped together under the same management at the UCL Cancer Institute. This paper explores the operational and financial interaction between the Pathology Facility and the Biobank over a period of 3 years (2017-2019). Since 2017, only a minority of the requests included collection of samples from the archive or molecular biology services, and most of the requests included histology services. Our data confirmed the difficulty for a biobank to achieve financial sustainability. The integration of the Pathology Facility with the Biobank within a single laboratory management and delivery infrastructure was shown to be an effective management option and presented a unique opportunity to overcome financial and operational challenges, thus improving efficiency and lowering costs for both parties.
Collapse
Affiliation(s)
- Adriana Alves
- Pathology Translational Technology Platform,
Cancer Institute,
University College LondonLondonUKUCL/UCLH Biobank for Studying Health and Disease,
Cancer Institute,
University College LondonLondon WC1E 6DEUK
- ADDRESS CORRESPONDENCE TO: Adriana Alves, Biobank and
Pathology Translational Technology Platform Technician, University
College London, Research Department of Pathology, Rockefeller
Building, Room 220, 2 Floor, 21 University Street,
London, WC1E 6DE (Phone: 020 7679 6029;
E-mail: or
)
| | - Amanda Gibbon
- UCL/UCLH Biobank for Studying Health and Disease,
Cancer Institute,
University College LondonLondon WC1E 6DEUK
| | - Sara Carvalho
- Pathology Translational Technology Platform,
Cancer Institute,
University College LondonLondonUKUCL/UCLH Biobank for Studying Health and Disease,
Cancer Institute,
University College LondonLondon WC1E 6DEUK
| | - Manuel Rodriguez-Justo
- Pathology Translational Technology Platform,
Cancer Institute,
University College LondonLondonUKucl/UCLH Biobank for Studying Health and Disease,
Cancer Institute, University College LondonLondonUKHistopathology–Cellular Pathology at University College London Hospitals,
NHS Foundation TrustLondon WC1E 6DEUK
| | - Elena Miranda
- Pathology Translational Technology Platform,
Cancer Institute,
University College LondonLondonUKUCL/UCLH Biobank for Studying Health and Disease,
Cancer Institute,
University College LondonLondon WC1E 6DEUK
| |
Collapse
|
6
|
Samuel G, Lucivero F, Lucassen AM. Sustainable biobanks: a case study for a green global bioethics. Glob Bioeth 2022; 33:50-64. [PMID: 35221664 PMCID: PMC8881066 DOI: 10.1080/11287462.2021.1997428] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2021] [Accepted: 10/21/2021] [Indexed: 11/24/2022] Open
Abstract
This paper argues that as we move to redefine global bioethics, there is a need to be attentive to the ethical issues associated with the environmental sustainability of data and digital infrastructures in global health systems. We show that these infrastructures have thus far featured little in environmental impact discussions in the context of health, and we use a case study approach of biobanking to illustrate this. We argue that this missing discussion is problematic because biobanks have environmental impacts associated with data and digital infrastructures. We consider several ethical questions to consider these impacts: what ethical work does the concept of environmental sustainability add to the debate; how should this concept be prioritised in decision-making; and who should be responsible for doing so? We call on global bioethics to play a role in advancing this dialogue and addressing these questions.
Collapse
Affiliation(s)
- G. Samuel
- Clinical Law and Ethics at Southampton (CELS), University of Southampton, Southampton General Hospital, Southampton, UK
- Department of Global Health and Social Medicine, King’s College London, London, UK
| | - F. Lucivero
- Ethox Centre and Wellcome Centre for Ethics and Humanities, Oxford University, Oxford, UK
| | - A. M. Lucassen
- Clinical Law and Ethics at Southampton (CELS), University of Southampton, Southampton General Hospital, Southampton, UK
| |
Collapse
|
7
|
Umpeleva TV, Vakhrusheva DV, Skornyakov SN. Biobank as a key component of supporting research in phthisiology and infectious diseases. КАРДИОВАСКУЛЯРНАЯ ТЕРАПИЯ И ПРОФИЛАКТИКА 2022. [DOI: 10.15829/1728-8800-2021-3084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Abstract
Conducting fundamental and clinical research in the field of tuberculosis is an important step towards reducing related morbidity and mortality, but access to a sufficient number of high-quality samples required for research is an unsolved problem in Russia. This review is devoted to biobanking as a key component of modern research in personalized medicine, as well as to the status and prospects for developing this area in phthisiology and infectious diseases combined with tuberculosis.
Collapse
Affiliation(s)
- T. V. Umpeleva
- National Medical Research Center of Phthisiopulmonology and Infectious Diseases
| | - D. V. Vakhrusheva
- National Medical Research Center of Phthisiopulmonology and Infectious Diseases
| | - S. N. Skornyakov
- National Medical Research Center of Phthisiopulmonology and Infectious Diseases
| |
Collapse
|
8
|
Akyüz K, Chassang G, Goisauf M, Kozera Ł, Mezinska S, Tzortzatou O, Mayrhofer MT. Biobanking and risk assessment: a comprehensive typology of risks for an adaptive risk governance. LIFE SCIENCES, SOCIETY AND POLICY 2021; 17:10. [PMID: 34903285 PMCID: PMC8666836 DOI: 10.1186/s40504-021-00117-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Accepted: 12/01/2021] [Indexed: 05/03/2023]
Abstract
Biobanks act as the custodians for the access to and responsible use of human biological samples and related data that have been generously donated by individuals to serve the public interest and scientific advances in the health research realm. Risk assessment has become a daily practice for biobanks and has been discussed from different perspectives. This paper aims to provide a literature review on risk assessment in order to put together a comprehensive typology of diverse risks biobanks could potentially face. Methodologically set as a typology, the conceptual approach used in this paper is based on the interdisciplinary analysis of scientific literature, the relevant ethical and legal instruments and practices in biobanking to identify how risks are assessed, considered and mitigated. Through an interdisciplinary mapping exercise, we have produced a typology of potential risks in biobanking, taking into consideration the perspectives of different stakeholders, such as institutional actors and publics, including participants and representative organizations. With this approach, we have identified the following risk types: economic, infrastructural, institutional, research community risks and participant's risks. The paper concludes by highlighting the necessity of an adaptive risk governance as an integral part of good governance in biobanking. In this regard, it contributes to sustainability in biobanking by assisting in the design of relevant risk management practices, where they are not already in place or require an update. The typology is intended to be useful from the early stages of establishing such a complex and multileveled biomedical infrastructure as well as to provide a catalogue of risks for improving the risk management practices already in place.
Collapse
Affiliation(s)
- Kaya Akyüz
- BBMRI-ERIC, Graz, Austria.
- Department of Science and Technology Studies, University of Vienna, Vienna, Austria.
| | - Gauthier Chassang
- BBMRI-ERIC, Graz, Austria
- CERPOP, Université de Toulouse, Inserm, Université Paul Sabatier, Toulouse, France
| | - Melanie Goisauf
- BBMRI-ERIC, Graz, Austria
- Department of Science and Technology Studies, University of Vienna, Vienna, Austria
| | | | - Signe Mezinska
- BBMRI-ERIC, Graz, Austria
- Institute of Clinical and Preventive Medicine, University of Latvia, Riga, Latvia
| | - Olga Tzortzatou
- BBMRI-ERIC, Graz, Austria
- Biomedical Research Foundation of the Academy of Athens, Athens, Greece
| | | |
Collapse
|
9
|
Miranda E, Pye H, Buckingham S, Alves A, Rodriguez-Justo M. Risk Assessment for Activity Regulated Under the Human Tissue Act: A Single Institution Experience. Biopreserv Biobank 2021; 20:217-223. [PMID: 34747640 DOI: 10.1089/bio.2021.0045] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Risk assessment represents one of the requirements for all activities involving human tissues within the premises. Although a variety of procedures are available to prepare risk assessments in general, there are no published examples of risks associated with the use of human samples in research. To cover this gap and to give an overview of the evaluation performed in our institution, we summarized the potential risks for the use of human samples in research identified in the projects under the remit of the UCL/UCLH Biobank. The procedures of acquisition, transportation, storage, use, and disposal of human samples, and security of the premises were analyzed. From our experience, there are governance-related risks associated with the process of consenting the patients, with the donor confidentiality, with mislabeling of samples and with the ethical approval associated with the project, and they generally do not compromise the integrity of the samples. On the other hand, samples' integrity is more at risk during collection, storage, transport, and use of the sample. Adequate training and having appropriate standard procedures in place and available for all staff seem to be the most effective control measures to prevent any issue. In addition, appropriate equipment maintenance, contingency plans, and strict regulation and monitoring of the facility security should always be in place. In summary, an appropriate evaluation of the risks associated with the use of human samples in research is one of the requirements for the use of human samples in research and it is fundamental for the protection of staff, students, the institution itself, and the patients. Supporting biobanking, implementing a culture of biosafety in the life sciences, and raising awareness in the scientific and regulatory communities are key ways to anticipate future problems associated with biological and governance risks.
Collapse
Affiliation(s)
- Elena Miranda
- Biobank and Pathology Translational Technology Platform, Cancer Institute, University College London, London, United Kingdom
| | - Hayley Pye
- Molecular Diagnostics and Therapeutics Group, Division of Surgery and Interventional Science, University College London, London, United Kingdom
| | - Sonia Buckingham
- Cancer Institute, University College London, London, United Kingdom
| | - Adriana Alves
- Biobank and Pathology Translational Technology Platform, Cancer Institute, University College London, London, United Kingdom
| | - Manuel Rodriguez-Justo
- Department of Cell Pathology, University College London Hospital, London, United Kingdom.,Research Department of Pathology, Cancer Institute, University College London, London, United Kingdom
| |
Collapse
|
10
|
Tarling T, Matzke LAM, Rush A, Gali B, Byrne JA, Watson PH. Vignettes to Illustrate the Value of Tumor Biobanks in Cancer Research in Canada. Biopreserv Biobank 2021; 20:75-83. [PMID: 34165356 DOI: 10.1089/bio.2021.0002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Background: Tumor biobanks are a common research infrastructure. As a collection of biospecimens and annotated data collected to support a multitude of research projects, biobanks facilitate access to materials that are the critical fuel for the generation of data in up to 40% of cancer research publications. However, quantifying how to measure biobanks' impact and their value on the field of cancer research discoveries and findings, has not been well elucidated. Methods: We have used a qualitative case study approach to illustrate the impact of tumor biobanks. We assessed the impact of three research studies published between 2010 and 2012 that required easily accessible "classic" biobanks. Each study utilized preassembled collections of tumor biospecimens with associated patient outcomes data at the outset of the research project. We compared the resulting journal impact factor, altmetric and field-weighted citation impact factor scores for each article to a set of six "benchmark" articles that represent cancer research and treatment discoveries from the same time period and two sentinel scientific discovery articles. Results: We developed a value model using a literature search and design-thinking methodologies to illustrate the contributions of these "classic" model biobanks to these research studies. Assessment of the three example articles supported by biobanks demonstrates that the output can have impact that is comparable to the impact of a set of benchmark articles describing milestones in the field of cancer research and cancer care. Conclusions: These case studies illustrate the value of the sustained investment of funds, planning, time, and effort on the part of the biobanks before the conduct of the research study to be able to ultimately support high-value research. The "value" model will enable further discussion around impact and may be useful in better delineating qualitative metrics of biobank value in the future.
Collapse
Affiliation(s)
- Tamsin Tarling
- Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Lise Anne Marie Matzke
- Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Amanda Rush
- School of Medical Sciences, Faculty Medicine and Health, The Children's Hospital at Westmead Clinical School, The University of Sydney, New South Wales, Australia.,New South Wales Statewide Biobank, New South Wales Health Pathology, Camperdown, New South Wales, Australia
| | - Brent Gali
- Biobanking and Biospecimen Research Services, Deeley Research Center, BC Cancer Victoria Center, Victoria, British Columbia, Canada
| | - Jennifer A Byrne
- New South Wales Statewide Biobank, New South Wales Health Pathology, Camperdown, New South Wales, Australia
| | - Peter H Watson
- Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.,Biobanking and Biospecimen Research Services, Deeley Research Center, BC Cancer Victoria Center, Victoria, British Columbia, Canada.,Canadian Tissue Repository Network, BC Cancer Research Center, Vancouver, British Columbia, Canada
| |
Collapse
|
11
|
Simeon-Dubach D, Henderson MK. Opportunities and Risks for Research Biobanks in the COVID-19 Era and Beyond. Biopreserv Biobank 2020; 18:503-510. [PMID: 33047969 PMCID: PMC7864089 DOI: 10.1089/bio.2020.0079] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
The SARS-CoV-2 pandemic, which caused a global outbreak of COVID-19 disease, has been a crisis of extraordinary proportions, causing serious impacts for research and public health. Biobanks have played a key important role in understanding the disease and response. In our article we will highlight the opportunities and risks of biobanks during and after the pandemic. The different aspects of safety and sustainability have and will be the main challenges for biobanks. Furthermore, the role of biobanks in biomedical research and public health has been emphasized as well as opportunities that have arisen for their participation in research.
Collapse
|
12
|
Allocca CM, Snapes E, Albert M, Bledsoe MJ, Castelhano MG, De Wilde M, Furuta K, Kozlakidis Z, Martin D, Martins A, McCall SJ, Schacter B. Biobanking in the COVID-19 Era and Beyond: Part 2. A Set of Tool Implementation Case Studies. Biopreserv Biobank 2020; 18:547-560. [PMID: 33226280 PMCID: PMC7757526 DOI: 10.1089/bio.2020.0083] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
The COVID-19 era has brought about a number of novel challenges for the global biobanking community. An array of diverse tools (e.g., standards, best practices, and plans) exists to support quality and fitness-for-purpose in biobank operations. The International Society for Biological and Environmental Repositories (ISBER) COVID-19 Response Task Force has set out to identify needs and gaps in these tools and make recommendations for the next generation of available tools, having closely examined the COVID-19-related challenges. While conducting this work to examine the relationships between tools and biobank adaptability, a subgroup of the task force conducted a parallel effort to develop and describe individual COVID-19 era case studies based on a number of operating biobanks. Each case study presents a different combination of implemented tools. Observations and lessons learned from these case studies are provided, and experiences with tool implementation are discussed. This information is supplemented by data relating to tool usefulness that was obtained through an ISBER survey discussed in a companion article. The knowledge gained from this study will be combined with other task force efforts to make recommendations to better position the biobanking community in their response to future emergencies.
Collapse
Affiliation(s)
- Clare M. Allocca
- Standards Coordination Office, National Institute of Standards and Technology, Gaithersburg, Maryland, USA
| | | | - Monique Albert
- Ontario Tumour Bank, Ontario Institute for Cancer Research, Toronto, Canada
| | | | - Marta G. Castelhano
- Cornell Veterinary Biobank, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA
| | | | - Koh Furuta
- Urayasu Warakuen Clinic, Urayasu, Japan
- International Agency for Research on Cancer, World Health Organization, Lyon, France
| | - Zisis Kozlakidis
- International Agency for Research on Cancer, World Health Organization, Lyon, France
| | - Dunja Martin
- Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures GmbH, Braunschweig, Germany
| | - Anabela Martins
- Micoteca da Universidade do Minho, Centro de Engenharia Biológica, Braga, Portugal
| | | | - Brent Schacter
- CancerCare Manitoba, University of Manitoba, Winnipeg, Canada
| |
Collapse
|
13
|
Sqalli H, El Awadi N, Rancati C. [Biobankonomics: the sustainability indicators of biobanks]. Med Sci (Paris) 2020; 36:282-285. [PMID: 32228851 DOI: 10.1051/medsci/2020043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- Hadi Sqalli
- MSc Biobanks and Complex Data Management, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Hôpital Pasteur, Biobanque BB-0033-00025, Nice, France
| | - Nora El Awadi
- MSc Biobanks and Complex Data Management, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Hôpital Pasteur, Biobanque BB-0033-00025, Nice, France
| | - Caroline Rancati
- MSc Biobanks and Complex Data Management, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Hôpital Pasteur, Biobanque BB-0033-00025, Nice, France
| |
Collapse
|
14
|
Henderson MK, Goldring K, Simeon-Dubach D. Advancing Professionalization of Biobank Business Operations: Performance and Utilization. Biopreserv Biobank 2019; 17:213-218. [PMID: 31188630 DOI: 10.1089/bio.2019.0005] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Biobanks are now in the spotlight as key enablers supporting preclinical, clinical, and environmental research. Awareness of their value has increased along with the need for these infrastructures to be sustained through business-focused practices. Following our 2017 pilot survey on biobank business planning, we initiated a more comprehensive 38-question multiple-language worldwide survey on biobank sustainability. Two hundred seventy-six biobanks of various sizes and stages of business planning (in place, in progress or none) responded. About two-thirds were established in the last 10 years. Survey results confirm our hypothesis that biobanks with business plans or preparing such plans are trending toward more professional structures. Specific survey data focusing on performance metrics and utilization, as related to sustainability, are presented. Biobanks most frequently measured basic performance metrics (sample utilization, samples collected, samples distributed, internal projects supported). Metrics less often reported included sample and data quality, cost recovery, citations, and publications, typically correlating with higher levels of biobank complexity and professionalism. Biobanks reported supporting projects for both internal and external use, with support of projects within their own organizations as the main driver of biobanks, independent of business plan status. Having a business plan seemed to be a key factor for biobanks that had developed sustained support for external commercial projects. While under half of the biobanks reported both target and actual utilization rates, the responses provided valuable data on utilization. Target utilization rates were much higher (2.5 to 5 times higher) than the rate of actual use. Many of the biobanks report less than 10% utilization. Biobanks with low utilization rates make sustainability a very distant and likely unreachable goal. Our survey has provided some basic data about biobank business planning globally. Continued research should be done, with the data and information shared within the community for the good of all biobank stakeholders.
Collapse
Affiliation(s)
- Marianne K Henderson
- 1 National Cancer Institute, National Institutes of Health (NIH), Bethesda, Maryland
| | - Kirstin Goldring
- 2 Sample Management, Discovery Science, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| | | |
Collapse
|
15
|
Cleynen I, Linsen L, Verstockt S, Verstockt B, Ballet V, Vandeput E, Van Assche G, Ferrante M, Van Landuyt K, Vermeire S, Ectors N. Inflammatory Bowel Disease (IBD)-A Textbook Case for Multi-Centric Banking of Human Biological Materials. Front Med (Lausanne) 2019; 6:230. [PMID: 31681784 PMCID: PMC6813565 DOI: 10.3389/fmed.2019.00230] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2019] [Accepted: 10/03/2019] [Indexed: 12/12/2022] Open
Abstract
Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory condition affecting mainly the gastro-intestinal tract with two main entities: Crohn's disease (CD) and ulcerative colitis (UC). Although the exact mechanisms underlying the initial development of IBD are not fully understood, it is believed that an abnormal immune response is elicited against the intestinal microbiota in genetically predisposed individuals. Crucial elements of the etiopathogenesis have been elucidated by research using human biological materials. The estimated prevalence of IBD is 0.5% in the Western world. Although incidence rates are increasing, both conditions are not "common" in general terms mandating a multicentric approach. Biological material from numerous Belgian patients have been collected over time in a number of university hospitals in Belgium (UH Ghent: 800 CD patients, 350 UC patients, 600 normal controls; UH Leuven: 2,600 CD patients, 1,380 UC patients, 98 IC/IBDU patients, 6,260 normal controls). Within the setting of the Flemish Center Medical Innovation (CMI) initiative and later on the Flemish biobank network a prospective study was set-up across three Belgian IBD centers (University Hospitals Brussels, Ghent, and Leuven). Human biological materials and data have been collected prospectively from newly diagnosed CD and UC patients. The analyses hereof have generated new insights which have been published in the most renowned journals. The approach of well-thought off, multi-centric, structured, and systematic biobanking has proven to be a success-story and thus a textbook case for multi-centric banking of human biological materials. This story is being told in this article.
Collapse
Affiliation(s)
- Isabelle Cleynen
- Laboratory for Complex Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium
| | - Loes Linsen
- Activity Center Biobanking, University Hospitals Leuven, Leuven, Belgium
| | - Sare Verstockt
- Laboratory for Complex Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium
| | - Bram Verstockt
- Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium
| | - Vera Ballet
- Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
| | - Eline Vandeput
- Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
| | - Gert Van Assche
- Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
| | - Marc Ferrante
- Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium.,Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
| | | | - Séverine Vermeire
- Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium.,Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
| | - Nadine Ectors
- Activity Center Biobanking, University Hospitals Leuven, Leuven, Belgium
| |
Collapse
|
16
|
Church TD, Richmond FJ. Biobank Continuity Management: A Survey of Biobank Professionals. Biopreserv Biobank 2019; 17:410-417. [PMID: 31017454 DOI: 10.1089/bio.2018.0142] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Academic biobanks face challenges that call for continuity and disaster planning. However, current regulations do not require such planning, so it is unclear if and how biobanks have prepared themselves to deal with future crises. This exploratory study used mixed methods to understand the state of continuity planning in U.S. biobanks. It first reviewed the current state of regulatory and implementation requirements that drive and challenge continuity planning. A survey instrument was then developed and critiqued by a focus group of experienced practitioners in biobanking. The refined survey was disseminated to a targeted group of respondents employed at biobanks across the United States. Most respondents were associated with relatively mature biobanks in operation for more than 6 years and these typically had some form of continuity plan in place. More commonly, continuity planning was reported to be focused on countering natural disasters rather than organization- or personnel-related crises. Respondents identified their most common limitation to be financial resources affecting all phases of implementation. Although many respondents appeared to be aware of some guidance documents and standards for continuity planning, many reported that they did not use or reference them when constructing their biobank continuity plans. Furthermore, nearly 25% of surveyed biobanks did not have a continuity plan and 61% indicated concern in having a mandated continuity plan. Results suggested academic organizations would benefit from a continuity plan template and best practice guidelines for plan development and implementation.
Collapse
Affiliation(s)
- Terry David Church
- Regulatory and Quality Sciences, University of Southern California (USC), USC School of Pharmacy, Los Angeles, California
| | - Frances J Richmond
- Regulatory and Quality Sciences, University of Southern California (USC), USC School of Pharmacy, Los Angeles, California
| |
Collapse
|
17
|
Henderson MK, Goldring K, Simeon-Dubach D. Advancing Professionalization of Biobank Business Operations: A Worldwide Survey. Biopreserv Biobank 2018; 17:71-75. [PMID: 30412417 DOI: 10.1089/bio.2018.0079] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Quality specimens from biobanks are key resources to support reproducible research. Sustaining biobanks requires robust management. We recently published a pilot survey that indicated that over half the participating biobanks had business plans in place and another third were working on business planning. While the results provided a clue to the status of business planning in biobanking, it was concluded that a longer and more in-depth survey and analysis were required. In April 2017, an extended survey was distributed worldwide in English, French, Chinese, German, and Spanish, through multiple channels. The survey was built using the Survey Monkey tool. Our hypothesis was that those biobanks that already have a business plan also have a more professional management structure. The questions were designed to understand more details about each biobank's business operations and communications. A total of 276 biobanks participated (China 65, France 40, United States 34, Spain 27, Germany 24, Australia 23, and rest of the world 63). About two thirds of the biobanks were established in the last 10 years. The responses provided data on the size of biobanks answering the survey, their status of business planning, and how and through what mediums they are communicating with customers. Biobanks with a business plan or preparing to have one showed a clear trend of having a customer strategy for marketing the samples and communicating with customers. No trend could be seen regarding websites and activities in social media. We confirmed our hypothesis that biobanks that have or are in the process of preparing a business plan are showing a trend toward more professional structures. In the biobanking community, the business mind-set and use of the business plan as a management tool have not quite arrived.
Collapse
Affiliation(s)
- Marianne K Henderson
- 1 National Cancer Institute, National Institutes of Health (NIH), Rockville, Maryland
| | - Kirstin Goldring
- 2 Sample Management, Discovery Science, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
| | | |
Collapse
|
18
|
Ensuring the Safety and Security of Frozen Lung Cancer Tissue Collections through the Encapsulation of Dried DNA. Cancers (Basel) 2018; 10:cancers10060195. [PMID: 29891792 PMCID: PMC6025404 DOI: 10.3390/cancers10060195] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2018] [Revised: 06/08/2018] [Accepted: 06/08/2018] [Indexed: 02/06/2023] Open
Abstract
Collected specimens for research purposes may or may not be made available depending on their scarcity and/or on the project needs. Their protection against degradation or in the event of an incident is pivotal. Duplication and storage on a different site is the best way to assure their sustainability. The conservation of samples at room temperature (RT) by duplication can facilitate their protection. We describe a security system for the collection of non-small cell lung cancers (NSCLC) stored in the biobank of the Nice Hospital Center, France, by duplication and conservation of lyophilized (dried), encapsulated DNA kept at RT. Therefore, three frozen tissue collections from non-smoking, early stage and sarcomatoid carcinoma NSCLC patients were selected for this study. DNA was extracted, lyophilized and encapsulated at RT under anoxic conditions using the DNAshell technology. In total, 1974 samples from 987 patients were encapsulated. Six and two capsules from each sample were stored in the biobanks of the Nice and Grenoble (France) Hospitals, respectively. In conclusion, DNA maintained at RT allows for the conservation, duplication and durability of collections of interest stored in biobanks. This is a low-cost and safe technology that requires a limited amount of space and has a low environmental impact.
Collapse
|
19
|
Tarling TE, Lasser F, Carter C, Matzke LA, Dhugga G, Arora N, Dee S, LeBlanc J, Babinsky S, O'Donoghue S, Cheah S, Watson P, Vercauteren SM. Business Planning for a Campus-Wide Biobank. Biopreserv Biobank 2017; 15:37-45. [DOI: 10.1089/bio.2016.0077] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
Affiliation(s)
- Tamsin E. Tarling
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
| | | | - Candace Carter
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
- Office of Biobank Education and Research (OBER), University of British Columbia, Vancouver, Canada
| | - Lise A.M. Matzke
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
- Office of Biobank Education and Research (OBER), University of British Columbia, Vancouver, Canada
| | - Gurm Dhugga
- BC Children's Hospital Research Institute, Vancouver, Canada
| | - Nidhi Arora
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
| | - Simon Dee
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
- Office of Biobank Education and Research (OBER), University of British Columbia, Vancouver, Canada
| | | | | | - Sheila O'Donoghue
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
- Office of Biobank Education and Research (OBER), University of British Columbia, Vancouver, Canada
| | - Stefanie Cheah
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
- Office of Biobank Education and Research (OBER), University of British Columbia, Vancouver, Canada
| | - Peter Watson
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
- Office of Biobank Education and Research (OBER), University of British Columbia, Vancouver, Canada
- BC Cancer Agency, Victoria, Canada
| | - Suzanne M. Vercauteren
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
- BC Children's Hospital Research Institute, Vancouver, Canada
- Department of Pathology and Laboratory Medicine, BC Children's Hospital, Vancouver, Canada
| |
Collapse
|